PMID- 35481063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231102
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 12
IP  - 19
DP  - 2022 Apr 13
TI  - A review on alpha-glucosidase inhibitory activity of first row transition metal 
      complexes: a futuristic strategy for treatment of type 2 diabetes.
PG  - 12011-12052
LID - 10.1039/d2ra00067a [doi]
AB  - Type 2 diabetes mellitus (T2DM) is characterized by high blood glucose levels and 
      has emerged as a controversial public health issue worldwide. The increasing 
      number of patients with T2DM on one hand, and serious long-term complications of 
      the disease such as obesity, neuropathy, and vascular disorders on the other 
      hand, have induced a huge economic impact on society globally. In this regard, 
      inhibition of alpha-glucosidase, the enzyme responsible for the hydrolysis of 
      carbohydrates in the body has been the main therapeutic approach to the treatment 
      of T2DM. As alpha-glucosidase inhibitors (alpha-GIs) have occupied a special position in 
      the current research and prescription drugs are generally alpha-GIs, researchers have 
      been encouraged to design and synthesize novel and efficient inhibitors. 
      Previously, the presence of a sugar moiety seemed to be crucial for designing 
      alpha-GIs since they can attach to the carbohydrate binding site of the enzyme 
      mimicking the structure of disaccharides or oligosaccharides. However, inhibitors 
      lacking glycosyl structures have also shown potent inhibitory activity and 
      development of non-sugar based inhibitors is accelerating. In this respect, in 
      vitro anti-alpha-glucosidase activity of metal complexes has attracted lots of 
      attention and this paper has reviewed the inhibitory activity of first-row 
      transition metal complexes toward alpha-glucosidase and discussed their probable 
      mechanisms of action.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Sohrabi, Marzieh
AU  - Sohrabi M
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran 
      momahdavi@tums.ac.ir.
FAU - Binaeizadeh, Mohammad Reza
AU  - Binaeizadeh MR
AUID- ORCID: 0000-0001-8521-761X
AD  - School of Chemistry, College of Science, University of Tehran Tehran Iran.
FAU - Iraji, Aida
AU  - Iraji A
AD  - Stem Cells Technology Research Center, Shiraz University of Medical Sciences 
      Shiraz Iran.
AD  - Central Research Laboratory, Shiraz University of Medical Sciences Shiraz Iran.
AD  - Liosa Pharmed Parseh Company Shiraz Iran.
FAU - Larijani, Bagher
AU  - Larijani B
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran 
      momahdavi@tums.ac.ir.
FAU - Saeedi, Mina
AU  - Saeedi M
AUID- ORCID: 0000-0002-4053-6331
AD  - Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of 
      Medical Sciences Tehran Iran m-saeedi@tums.ac.ir.
AD  - Persian Medicine and Pharmacy Research Center, Tehran University of Medical 
      Sciences Tehran Iran.
FAU - Mahdavi, Mohammad
AU  - Mahdavi M
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 
      Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran 
      momahdavi@tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220420
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9020348
COIS- There are no conflicts to declare.
EDAT- 2022/04/29 06:00
MHDA- 2022/04/29 06:01
PMCR- 2022/04/20
CRDT- 2022/04/28 06:35
PHST- 2022/01/05 00:00 [received]
PHST- 2022/04/12 00:00 [accepted]
PHST- 2022/04/28 06:35 [entrez]
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/04/29 06:01 [medline]
PHST- 2022/04/20 00:00 [pmc-release]
AID - d2ra00067a [pii]
AID - 10.1039/d2ra00067a [doi]
PST - epublish
SO  - RSC Adv. 2022 Apr 20;12(19):12011-12052. doi: 10.1039/d2ra00067a. eCollection 
      2022 Apr 13.